Other Clinical Trial - Study on Heart Failure With Preserved Ejection

Status Recruiting

Clinical Trial Summary

With the cardiopulmonary exercise testing as the primary outcome, the study aims to evaluate the efficacy of Qishen Granules on cardiac function, quality of life and biomarker level of patients with heart failure with preserved ejection fraction (HFpEF), which will provide evidence for the treatment of HFpEF with traditional Chinese medicine.

Clinical Trial Description

Heart failure with preserved ejection fraction (HFpEF) is common and is associated with high morbidity and mor-tality in China. Studies have shown that traditional Chinese medicine (TCM) combined with conventional Western medicine has a good effect on improving exercise tolerance and quality of life in patients with HFpEF, but there are still some shortcomings that limit the reliability and extrapolation of results. Based on TCM theory and our decades of experience, we developed Qishen Granules for therapeutic use in the treatment of HFpEF. The good effect of Qishen Granules in patients with heart failure has been clinically verified before. In this study, cardiopulmonary exercise test (CPET) was used to evaluate the peak oxygen consumption (peak VO2), which is the gold standard assessment of aerobic capacity. Therefore, we selected VO2 peak as the primary outcome. At the same time, we conducted a preliminary assessment of the efficacy of Qishen Granules in improving the quality of life in patients with HFpEF, using Kansas City Cardiomyopathy Questionnaire (KCCQ) as the secondary outcome, and combined with other CPET indicators, echocardiographic measures, NT-pro BNP level, growth STimulation expressed gene 2 (ST2), biomarkers of liver and kidney function, and TCM Four-Dimensional Diagnostic Information Scale (TCMFDIS) to objectively, accurately, and comprehensively evaluate the efficacy and safety of Qishen Granules in improving quality of life and exercise capacity in patients with HFpEF. ;

Study Design

Related Conditions & MeSH terms

Heart Failure
Heart Failure With Preserved Ejection Fraction

Clinical Trial Details

NCT number	NCT06377761
Study type	Interventional
Source	Guangdong Provincial Hospital of Traditional Chinese Medicine
Contact	Lei Wang, doctorate
Phone	8620-81887233-3280
Email	Dr.wanglei@139.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2023
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05839730` - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT05095688` - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting	`NCT06379152` - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05676684` - Dapagliflozin, Spironolactone or Both for HFpEF	Phase 2/Phase 3
Recruiting	`NCT04153136` - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)	Phase 2
Recruiting	`NCT06114498` - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05715697` - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT04745013` - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart	N/A
Completed	`NCT05586828` - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Completed	`NCT05126836` - Cilostazol for HFpEF	Phase 2
Recruiting	`NCT04594499` - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting	`NCT05204238` - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed	`NCT04535726` - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting	`NCT03550235` - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed	`NCT04633460` - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure	Phase 2
Completed	`NCT06228807` - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting	`NCT05284617` - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF	Phase 2
Recruiting	`NCT05562063` - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients	Phase 4
Recruiting	`NCT06027307` - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation	Phase 3
Recruiting	`NCT05582044` - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study on Heart Failure With Preserved Ejection Fraction With Qishen Granules

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms